MYH-associated polyposis signature (MAP). VectraDA- VectraDA is a protein detection test for assessing the disease activity of rheumatoid arthritis. The company’s Vectra DA test is a quantitative, objective multi-biomarker blood test validated to measure rheumatoid arthritis (RA) disease activity. Vectra DA assesses multiple mechanisms and pathways associated with RA disease activity and integrates the concentrations of 12 serum proteins into a single score reported on a scale of 1 to 100. Prolaris-Prolaris is a RNA expression test for assessing the aggressiveness of prostate cancer. The company’s Prolaris test is a gene expression assay that assesses whether a patient is likely to have a slow growing, indolent form of prostate cancer that can be safely monitored through active surveillance, or a more aggressive form of the disease that would warrant aggressive intervention, such as a radical prostatectomy or radiation therapy. The Prolaris test was developed to improve physicians’ ability to predict disease outcome and to thereby optimize patient treatment. EndoPredict-EndoPredict is a RNA expression test for assessing the aggressiveness of breast cancer. The EndoPredict test is a RNA expression test used to determine which women with breast cancer would benefit from chemotherapy. EndoPredict predicts the likelihood of metastases to help guide treatment decisions for chemotherapy and extended anti-hormonal therapy. EndoPredict has been shown to predict cancer-specific disease progression and metastases with no confusing intermediate results in 13 published clinical studies with more than 2,200 patients and is CE marked. myPath Melanoma-RNA expression test for diagnosing melanoma. The company’s myPath Melanoma test is a gene expression based profile that is performed on biopsy tissue for the purpose of aiding a dermatopathologist in the diagnosis of melanoma. myChoice HRD-Companion diagnostic to measure three modes of homologous recombination deficiency (HRD), including loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions in cancer cells. The company’s myChoice HRD test is the a homologous recombination deficiency test to detect when a tumor has lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. The myChoice HRD score is a composite of three proprietary technologies, including loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions. Positive myChoice HRD scores, reflective of DNA repair deficiencies, are prevalent in all breast cancer subtypes, ovarian and most other major cancers. myPlan Lung CancerRNA expression test for assessing the aggressiveness of lung cancer. The company’s myPlan Lung Cancer test is a gene expression based profile that might aid a physician in making a determination as to the aggressiveness of a patient’s lung cancer and based upon this determination more accurately guide patient therapy. Pharmaceutical and Clinical Services Through Myriad RBM, the company provides biomarker discovery and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries utilizing its multiplexed immunoassay technology. Its technology enables it to screen large sets of well-characterized clinical samples from both diseased and non-diseased populations against its extensive menu of biomarkers. In February 2015, the company completed the acquisition of Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG (the Clinic). Business Strategy The company’s strategy is focused on executing strategic imperatives that include transition and expansion of the hereditary cancer market, launching new products across a diverse set of disease indications, and expanding its molecular diagnostic business internationally. Sales and Marketing The company sells its tests through its own direct sales force and marketing efforts in the United States, Europe, Australia and Canada. Its United States sales force is comprised of approximately 502 individuals across five separate sales channels. The c
myriad genetics inc (MYGN:NASDAQ GS)
320 Wakara Way
Salt Lake City, UT 84108
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for MYGN.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact MYRIAD GENETICS INC, please visit www.myriad.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.